Emerging oligonucleotide therapeutics for rare neuromuscular diseases
Research and drug development concerning rare diseases are at the cutting edge of scientific technology. To date, over 7,000 rare diseases have been identified. Despite their individual rarity, 1 in 10 individuals worldwide is affected by a rare condition. For the majority of these diseases, there i...
Автори: | Aoki, Y, Wood, MJA |
---|---|
Формат: | Journal article |
Мова: | English |
Опубліковано: |
IOS Press
2021
|
Схожі ресурси
Схожі ресурси
-
Oligonucleotide-based therapies for neuromuscular disease
за авторством: Douglas, A, та інші
Опубліковано: (2015) -
Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases
за авторством: Tsoumpra, MK, та інші
Опубліковано: (2019) -
Advances in oligonucleotide drug delivery
за авторством: Roberts, TC, та інші
Опубліковано: (2020) -
Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseases
за авторством: Ashok Verma
Опубліковано: (2018-01-01) -
Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment
за авторством: Gait, M, та інші
Опубліковано: (2018)